IL17A and B-cell non-Hodgkin lymphoma: Overexpressed IL-23 enhances antitumor activity in SU-DHL-4 human B cell lymphoma cell inoculated xenograft model [71], however, it is also regulated that endogenous IL-23 promotes pro-tumor activity through STAT3 activation by inducing inflammatory responses including IL-17 production [72].